Search
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalBased upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental … After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalMaralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat. Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, pa...
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239]
Etoricoxib
go.drugbank.com/drugs/DB01628ApprovedInvestigationalWithdrawnIt is approved in more than 60 countries worldwide but not in the US.
Tiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigational[A274073] Tiratricol is currently being investigated in US clinical trials.
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436ApprovedTechnetium Tc-99m (99mTc) succimer, also known as technetium Tc-99m dimercaptosuccinic acid (DMSA), is a radioactive diagnostic agent used to evaluate functional renal tissue and tubular function in patients with renal parenchymal disord...
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigationalCrovalimab is a humanized monoclonal antibody and complement C5 inhibitor. It consists of two heavy chains (451 amino acid residues each) and two light chains (217 amino acid residues each). First developed by Chugai Pharmaceutical, in c...
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnRegdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme ...